AI Article Synopsis

  • A study was conducted to assess the impact of direct-acting antiviral (DAA) treatments on the recurrence and aggressiveness of hepatocellular carcinoma (HCC) in patients with hepatitis C virus (HCV) in North America.
  • The research analyzed 793 patients, with a focus on 304 who received DAA therapy and 489 who did not, finding that DAA treatment did not significantly affect HCC recurrence rates.
  • Although DAA-treated patients had a slightly higher chance of receiving potentially curative treatments for recurrences, the differences were not statistically significant, indicating similar outcomes between treated and untreated groups.

Article Abstract

Background & Aims: There is controversy over the effects of direct-acting antiviral (DAA) therapies for hepatitis C virus (HCV) infection on hepatocellular carcinoma (HCC) recurrence and tumor aggressiveness. We compared HCC recurrence patterns between DAA-treated and untreated HCV-infected patients who had achieved a complete response to HCC treatment in a North American cohort.

Methods: We conducted a retrospective cohort study of patients with HCV-related HCC with a complete response to resection, local ablation, transarterial chemo- or radioembolization, or radiation therapy from January 2013 through December 2017 at 31 health systems throughout the United States and Canada. Cox regression was used to examine the association between DAA therapy and time to recurrence after a complete response, with DAA therapy analyzed as a time-varying exposure. We also estimated the association between DAA therapy and risk of early HCC recurrence (defined as 365 days after complete response).

Results: Of 793 patients with HCV-associated HCC, 304 (38.3%) received DAA therapy and 489 (61.7%) were untreated. HCC recurred in 128 DAA-treated patients (42.1%; early recurrence in 52 patients) and 288 untreated patients (58.9%; early recurrence in 227 patients). DAA therapy was not associated with HCC recurrence (hazard ratio 0.90, 95% confidence interval 0.70-1.16) or early HCC recurrence (hazard ratio 0.96, 95% confidence interval 0.70-1.34) after we adjusted for study site, age, sex, Child-Pugh score, α-fetoprotein level, tumor burden, and HCC treatment modality. In DAA-treated and untreated patients, most recurrences were within the Milan criteria (74.2% vs 78.8%; P = .23). A larger proportion of DAA-treated than untreated patients received potentially curative HCC therapy for recurrent HCC (32.0% vs 24.6%) and achieved a complete or partial response (45.3% vs 41.0%) but this did not achieve statistical significance.

Conclusion: In a large cohort of North American patients with complete response to HCC treatment, DAA therapy was not associated with increased overall or early HCC recurrence. HCC recurrence patterns, including treatment response, were similar in DAA-treated and untreated patients.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6598433PMC
http://dx.doi.org/10.1053/j.gastro.2019.01.027DOI Listing

Publication Analysis

Top Keywords

hcc recurrence
28
daa therapy
24
daa-treated untreated
16
complete response
16
untreated patients
16
hcc
15
therapy associated
12
north american
12
hcc treatment
12
early hcc
12

Similar Publications

METTL4 and METTL5 as biomarkers for recurrence-free survival in hepatocellular carcinoma patients.

Future Oncol

December 2024

Department of Hepatobiliary and Pancreatic Surgery, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.

Background: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths, with high rates of postoperative recurrence. Identifying reliable biomarkers for predicting recurrence is critical for improving patient outcomes. This study investigates the predictive value of m6A methylation-related genes, METTL4 and METTL5, on HCC recurrence after surgery.

View Article and Find Full Text PDF

Serum Galectin-9 mirrors immune-evasive microenvironment and predicts early recurrence in hepatocellular carcinoma.

Gene

December 2024

Department of Laboratory Medicine, Zhongshan Hospital, Fudan University, Shanghai, China; Cancer Center, Shanghai Zhongshan Hospital, Fudan University, Shanghai, China; Department of Laboratory Medicine, Xiamen Branch, Zhongshan Hospital, Fudan University, Xiamen, China; Department of Laboratory Medicine, Wusong Branch, Zhongshan Hospital, Fudan University, Shanghai, China. Electronic address:

Background: The precise role of Galectin-9, an immune checkpoint protein involved in immune responses, in hepatocellular carcinoma (HCC) remains elusive. Importantly, the prognostic value of serum Galectin-9 has not been clarified, and its association with infiltrating immune characteristics was unclear.

Methods: The association between serum Galectin-9 concentration and HCC recurrence was analyzed in two cohorts of HCC patients (training 133; validation 97) who received curative resection during 2018 and 2019.

View Article and Find Full Text PDF

Background And Purpose: Liver cancer has a high recurrence rate of 50%~70% for early-stage patients. Minimal residual disease (MRD) is strongly linked to liver cancer early recurrence. Identifying MRD through reliable prognostic biomarkers, such as circulating tumor DNA (ctDNA), could significantly benefit these patients by enabling timely intervention and improved outcomes.

View Article and Find Full Text PDF

MRI-based prediction of microvascular invasion/high tumor grade and adjuvant therapy benefit for solitary HCC ≤ 5 cm: a multicenter cohort study.

Eur Radiol

December 2024

Department of Radiology, Functional and Molecular Imaging Key Laboratory of Sichuan Province, West China Hospital, Sichuan University, Chengdu, Sichuan, China.

Article Synopsis
  • - The study aimed to create and validate an MRI-based model to diagnose microvascular invasion (MVI) and high-risk histopathology in patients with small hepatocellular carcinoma (HCC) and to predict benefits from adjuvant therapy.
  • - Researchers conducted a retrospective analysis on 577 patients, using various clinical and MRI features to develop the model, which was then validated across multiple hospitals.
  • - They found that specific traits, including high serum α-fetoprotein levels and non-simple nodular growth, indicated worse recurrence-free survival, but patients showing these high-risk traits did benefit from adjuvant therapy.
View Article and Find Full Text PDF

Objectives: Despite increasing interest, prospective data on the use of degradable starch microsphere-transarterial chemoembolization (DSM-TACE) in the management of patients with unresectable HCC are still scarce. The objective of the HepaStar study was to collect prospective safety and effectiveness data in a prospective multicenter observational study.

Materials And Methods: Between January 2017 and December 2022, consecutive participants with unresectable or recurrent HCC treated with DSM-TACE as standard of care at 6 participating centers in Europe were enrolled.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!